Stevanato Group S.p.A. (STVN)
USD 21.38
(3.09%)
USD 21.38
(3.09%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 200.72 Million EUR | 22.17% |
| 2022 | 152.57 Million EUR | 19.09% |
| 2021 | 128.11 Million EUR | 24.25% |
| 2020 | 103.1 Million EUR | 65.72% |
| 2019 | 62.22 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 24.08 Million EUR | -59.51% |
| 2024 Q2 | 27.16 Million EUR | 16.12% |
| 2023 Q1 | 40.64 Million EUR | -35.58% |
| 2023 FY | 186.39 Million EUR | 22.17% |
| 2023 Q4 | 59.49 Million EUR | 16.19% |
| 2023 Q3 | 51.2 Million EUR | 14.03% |
| 2023 Q2 | 44.9 Million EUR | 10.46% |
| 2022 Q2 | 43.83 Million EUR | 15.62% |
| 2022 Q1 | 37.91 Million EUR | -12.83% |
| 2022 FY | 152.57 Million EUR | 19.09% |
| 2022 Q4 | 63.1 Million EUR | 32.69% |
| 2022 Q3 | 47.55 Million EUR | 8.48% |
| 2021 Q1 | 42.93 Million EUR | 13.3% |
| 2021 FY | 128.11 Million EUR | 24.25% |
| 2021 Q4 | 43.5 Million EUR | 54.08% |
| 2021 Q3 | 28.23 Million EUR | -40.68% |
| 2021 Q2 | 47.59 Million EUR | 10.84% |
| 2020 Q4 | 37.9 Million EUR | 67.04% |
| 2020 FY | 103.1 Million EUR | 65.72% |
| 2020 Q3 | 22.68 Million EUR | -16.39% |
| 2020 Q2 | 27.13 Million EUR | 76.39% |
| 2020 Q1 | 15.38 Million EUR | 0.0% |
| 2019 FY | 62.22 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alcon Inc. | 1.03 Billion USD | 80.681% |
| AptarGroup, Inc. | 404.01 Million USD | 50.319% |
| Baxter International Inc. | 390 Million USD | 48.533% |
| Becton, Dickinson and Company | 2.42 Billion USD | 91.723% |
| Bausch + Lomb Corporation | 130 Million USD | -54.4% |
| Haemonetics Corporation | 164.88 Million USD | -21.735% |
| Envista Holdings Corp | 31.5 Million USD | -537.206% |
| ResMed Inc. | 1.31 Billion USD | 84.793% |
| Teleflex Incorporated | 506.31 Million USD | 60.357% |
| Warby Parker Inc. | -71.99 Million USD | 378.793% |
| West Pharmaceutical Services, Inc. | 676 Million USD | 70.308% |